Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Illumina Inc Market Cap
From what 18 stock analysts predict, the share price for Illumina Inc (ILMN) might increase by 5.9% in the next year. This is based on a 12-month average estimation for ILMN. Price targets go from $105 to $252. The majority of stock analysts believe ILMN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ILMN is a stock in Healthcare which has been forecasted to be worth $149.78 as an average. On the higher end, the forecast price is $252 USD by from and on the lower end ILMN is forecasted to be $105 by from .
These are the latest 20 analyst ratings of ILMN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jasper Hellweg Argus Research | Buy | $150 | Upgrade | Aug 28, 2024 |
| Narumi Nakagiri Daiwa Capital | Buy | $154 | Upgrade | Aug 16, 2024 |
| Sung Ji Nam Scotiabank | Sector Outperform | $164 | Maintains | Aug 15, 2024 |
| Conor McNamara RBC Capital | Outperform | $242 | Reiterates | Aug 14, 2024 |
| Dan Brennan TD Cowen | Buy | $144 | Upgrade | Aug 14, 2024 |
| Luke Sergott Barclays | Equal-Weight | $125 | Upgrade | Aug 14, 2024 |
| David Westenberg Piper Sandler | Overweight | $195 | Maintains | Aug 13, 2024 |
| Julia Qin JP Morgan | Neutral | $125 | Maintains | Aug 7, 2024 |
| John Sourbeer UBS | Neutral | $133 | Maintains | Aug 7, 2024 |
| Catherine Ramsey Baird | Neutral | $124 | Maintains | Aug 7, 2024 |
| Dan Brennan TD Cowen | Hold | $126 | Maintains | Aug 7, 2024 |
| Conor McNamara RBC Capital | Outperform | $242 | Reiterates | Aug 7, 2024 |
| Patrick Donnelly Citigroup | Buy | $155 | Maintains | Aug 7, 2024 |
| Patrick Donnelly Citigroup | Buy | $140 | Upgrade | Jul 10, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $170 | Reiterates | Jul 10, 2024 |
| Conor McNamara RBC Capital | Outperform | $242 | Maintains | Jul 1, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $175 | Maintains | Jun 11, 2024 |
| Dan Brennan TD Cowen | Hold | $122 | Maintains | Jun 6, 2024 |
| Tycho Peterson Jefferies | Hold | $115 | Assumes | Jun 3, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $170 | Reiterates | May 7, 2024 |
When did it IPO
2000
Staff Count
10,590
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Jacob Thaysen Ph.D.
Market Cap
$22.53B
In 2023, ILMN generated $4.50B in revenue, which was a decrease of -1.75% from the previous year. This can be seen as a signal that ILMN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - GRAIL Inc., spun off from Illumina in June 2024, reported a Q2 2024 operational loss of $1.64 billion. The company plans to restructure, focusing on its Galleri test and extending its cash runway to 2028.
Why It Matters - GRAIL's significant operational loss and restructuring efforts highlight financial risks, yet its potential growth from the Galleri test may attract investors looking for long-term gains.
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Earnings results have driven a significant increase in stock prices, following a pullback, suggesting a potential investment opportunity.
Why It Matters - A significant earnings increase suggests strong company performance, while a pullback may offer a buying opportunity at a lower price, potentially enhancing future returns.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - The FDA has approved Illumina's TruSight Oncology Comprehensive Assay, a significant advancement in cancer diagnostics.
Why It Matters - FDA approval of Illumina's assay enhances its market position in cancer diagnostics, potentially increasing revenue and attracting investment amid growing demand for precision medicine.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Illumina, Inc. (NASDAQ: ILMN) received a favorable ruling from the European Court of Justice, stating the European Commission lacks jurisdiction over its acquisition of GRAIL.
Why It Matters - Illumina's favorable ruling on its GRAIL acquisition reduces regulatory risks and may enhance growth prospects, positively impacting its stock performance and investor confidence.
Tue, 03 Sep 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Europe's top court supports Illumina in its challenge against EU antitrust regulators regarding its $7.1 billion acquisition of Grail, a cancer diagnostic company.
Why It Matters - Illumina's court victory reduces regulatory risks for its acquisition of Grail, potentially boosting growth prospects and investor confidence in the company’s future performance.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - GRAIL, Inc. reported that findings on its Galleri® multi-cancer early detection test showed effectiveness in identifying aggressive prostate cancers, published in JCO Precision Oncology.
Why It Matters - Positive data on Galleri's ability to detect aggressive prostate cancers may enhance GRAIL's market position and investor confidence, potentially impacting stock performance and future partnerships.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
